Personal protective equipment with functionalized nanotube compositions to control pathogens such as SARS CoV-2 (coronavirus)
Nanotube compositions may be employed in many different forms alone, and/or with surfactants, with antiviral metals, with antigens, and/or with various drugs to control pathogens like viruses e.g., SARS COVID-2, bacteria, mold, fungi, chemical or biological agents etc in masks or other personal protection equipment. The personal protection equipment such as masks reduce, control, absorb, deactivate, detoxify, and/or kill the pathogens such that a pathogen or pathogens deleterious effects are reduced and/or eliminated to a user of the mask.
1. A mask comprising at least one layer comprising a plurality of discrete carbon nanotubes in an amount of from about 0.5 g to about 2 g of nanotubes per square meter of said layer and at least one surfactant wherein the mask further comprises polypropylene with a melt flow rate of from about 1 to about 500 g/10 min. and wherein the mask further comprises a coronavirus at least partially adhered to the plurality of discrete carbon nanotubes.
2. The mask of claim 1 wherein the mask meets or exceeds May 11, 2020 requirements to be approved as a surgical N95 respirator by the FDA.
3. The mask of claim 1 wherein the mask comprises from 2 to 7 layers wherein a comfort layer is configured to be nearest a user's skin.
4. The mask of claim 1 wherein the mask comprises one or more elastic bands and the surfactant is a crosslinked polyvinylalcohol.
5. The mask of claim 1 wherein the mask comprising the at least one layer comprising the plurality of discrete carbon nanotubes comprises nanotubes in an amount of from about 0.75 g to about 2 g of nanotubes per square meter of said layer.
6. The mask of claim 1 wherein the mask comprising the at least one layer comprising the plurality of discrete carbon nanotubes comprises nanotubes in an amount of from about 1.0 g to about 2 g of nanotubes per square meter of said layer.
7. The mask of claim 1 wherein the mask comprising the at least one layer comprising the plurality of discrete carbon nanotubes comprises nanotubes in an amount of from about 0.75 g to about 1.0 g of nanotubes per square meter of said layer.
8. The mask of claim 1 wherein the mask comprising the at least one layer comprising the plurality of discrete carbon nanotubes comprises nanotubes in an amount of from about 0.5 g to about 1 g of nanotubes per square meter of said layer.
9. The mask of claim 1 wherein the polypropylene has a melt flow rate of from about 20 to about 500 g/10 min. according to ASTM D1238 2.16 kg 230° C.
10. The mask of claim 1 wherein the polypropylene has a melt flow rate of from about 1 to about 100 g/10 min. according to ASTM D1238 2.16 kg 230° C.
11. The mask of claim 1 wherein the polypropylene has a melt flow rate of from about 20 to about 100 g/10 min. according to ASTM D1238 2.16 kg 230° C.
12. The mask of claim 1 wherein the mask comprises from 2 to 4 layers.
13. The mask of claim 1 wherein the at least one surfactant is a polylactic acid, a polyvinyl alcohol, a polyethylene oxide, a polyglycolic acid, polyvinylpyrrolidone, a polyacrylic acid, carboxy methyl cellulose, a peptide, a polysaccharide, or a protein.
14. The mask of claim 1 wherein the at least one surfactant is a crosslinked polyvinylalcohol.
15. The mask of claim 1 wherein the mask further comprises activated carbon.
16. A mask comprising at least one layer comprising a plurality of discrete carbon nanotubes in an amount of from about 2 g to about 25 g of nanotubes per square meter of said layer and at least one surfactant wherein the mask further comprises polypropylene with a melt flow rate of from about 1 to about 500 g/10 min. and wherein the mask further comprises a coronavirus at least partially adhered to the plurality of discrete carbon nanotubes.
17. The mask of claim 16 wherein the at least one surfactant is a crosslinked polyvinylalcohol.
18. The mask of claim 16 wherein the mask meets or exceeds May 11, 2020 requirements to be approved as a surgical N95 respirator by the FDA.
19. The mask of claim 16 wherein the mask comprises from 2 to 7 layers.